+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Urinary Tract Infection Market - Global Forecast 2026-2032- Product Image
Urinary Tract Infection Market - Global Forecast 2026-2032- Product Image
Sale

Urinary Tract Infection Market - Global Forecast 2026-2032

  • Report

  • 189 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4986010
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Urinary Tract Infection Market is projected to reach USD 10.96 Billion in 2026. It is expected to continue growing at a CAGR of 7.15%, reaching USD 16.62 Billion by 2032.

Urinary tract infection (UTI) remains one of the most common bacterial infections across community, outpatient, long-term care, and hospital settings. Clinical literature consistently identifies Escherichia coli as the leading cause of uncomplicated UTI, while recurrent UTI, catheter-associated UTI (CAUTI), pregnancy-related UTI, diabetes-associated UTI, and infections in older adults increase diagnostic and therapeutic complexity.

The UTI industry landscape is shaped by high patient volumes, rising antimicrobial resistance, demand for rapid UTI diagnostics, expanded telehealth triage, and renewed interest in non-antibiotic UTI prevention. Industry leaders are prioritizing stewardship-aligned antibiotics, point-of-care testing, molecular diagnostics, vaccine research, microbiome-based approaches, and digital care pathways that reduce avoidable prescribing while improving patient outcomes.

Transformative Shifts in the UTI Landscape

The urinary tract infection landscape is shifting from empiric treatment toward evidence-based, risk-stratified care. Antimicrobial resistance is the strongest catalyst: surveillance programs in the United States, Europe, and Asia report increasing resistance among uropathogens, especially fluoroquinolone resistance and extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales. This is accelerating demand for culture-guided therapy, local antibiogram integration, and rapid antimicrobial susceptibility testing.

Care delivery is also transforming. Retail clinics, telemedicine platforms, and home-based sample collection are expanding access for uncomplicated UTI, while hospitals focus on CAUTI prevention bundles, catheter-use reduction, and infection-control analytics. At the same time, women’s health investment, aging demographics, diabetes prevalence, and the burden of recurrent UTI are creating demand for preventive solutions beyond traditional antibiotics.

Cumulative Impact of Artificial Intelligence on UTI Care

Artificial intelligence is becoming a practical enabler across the UTI value chain. In diagnostics, AI-supported urinalysis interpretation, image-based microscopy, and machine learning models can help flag contaminated samples, predict culture positivity, and prioritize specimens for confirmatory testing. In clinical decision support, algorithms can incorporate symptoms, pregnancy status, renal function, prior cultures, allergies, and local resistance patterns to support stewardship-aligned prescribing.

AI is also influencing drug discovery and population health. Predictive models can identify patients at higher risk of recurrent UTI or CAUTI, while hospital analytics can monitor catheter days, adherence to prevention bundles, and antibiotic utilization. The greatest commercial impact will come from validated AI tools that demonstrate clinical utility, interoperability with electronic health records, transparent performance across populations, and compliance with medical device and data privacy regulations.

Key Regional Insights Across the UTI Market

North America benefits from mature diagnostic infrastructure, strong antimicrobial stewardship programs, and high adoption of telehealth for uncomplicated UTI management, with U.S. and Canadian public health agencies continuing to emphasize appropriate antibiotic use and healthcare-associated infection prevention. Europe is shaped by national antibiotic stewardship policies, European Association of Urology guidance, coordinated antimicrobial resistance surveillance, and widespread emphasis on reducing inappropriate antibiotic exposure. Asia-Pacific is expanding access to UTI diagnosis and care through large patient populations, rising healthcare utilization, and increasing investments in clinical laboratories, though uneven access to urine culture testing and variable antibiotic use remain persistent challenges.

Latin America is seeing greater demand for affordable UTI diagnostics and standardized treatment pathways as public and private healthcare systems address resistance and recurrent infection burden, particularly in urban centers with expanding laboratory networks. The Middle East is strengthening tertiary-care capacity and infection prevention programs, especially in advanced hospital networks across the region where CAUTI prevention, stewardship, and digital health modernization are policy priorities. Africa faces the dual challenge of underdiagnosis and limited laboratory access in many settings, creating opportunities for low-cost point-of-care diagnostics, surveillance expansion, antimicrobial stewardship education, and practical care pathways suited to resource-variable environments.

Key Group Insights for UTI Market Growth

Within ASEAN, UTI demand is influenced by expanding primary care access, urbanization, rising chronic disease burden, and the need for cost-effective diagnostics that can operate in both centralized laboratories and decentralized care settings. The GCC is characterized by high healthcare investment, advanced hospital systems, and growing attention to antimicrobial stewardship, particularly for complicated UTI, CAUTI management, and infection-control performance across tertiary facilities. The European Union remains a benchmark for coordinated antimicrobial resistance surveillance, regulatory rigor, stewardship-driven prescribing, and guideline-based UTI management.

BRICS countries represent large-volume opportunities driven by population scale, rising diabetes and aging-related risk factors, and expanding diagnostic capacity, but they also face significant resistance-management challenges that require improved surveillance and rational prescribing. G7 markets are differentiated by higher adoption of molecular diagnostics, digital health tools, robust laboratory quality systems, and regulated clinical pathways for outpatient and hospital-based UTI care. NATO-aligned healthcare systems, while diverse, generally emphasize health security, resilient medical supply chains, and preparedness against antimicrobial resistance as a strategic public health threat affecting infection management.

Key Country Insights in the UTI Market

The United States has strong demand for telehealth-enabled UTI care, rapid diagnostics, and CAUTI reduction programs, supported by CDC antimicrobial stewardship initiatives and hospital quality reporting. Canada emphasizes prudent antibiotic use, primary care access, and surveillance, while Mexico and Brazil show opportunities for affordable diagnostics, standardized prescribing, and expanded laboratory capacity as healthcare systems address recurrent UTI and antimicrobial resistance. In the United Kingdom, national guidance and antimicrobial stewardship strongly influence prescribing behavior, while Germany and France combine advanced diagnostics with structured healthcare reimbursement, laboratory networks, and surveillance systems.

Italy and Spain face meaningful recurrent UTI and older-adult care needs, reinforcing demand for prevention strategies and rapid testing. Russia’s market is influenced by large population needs, infectious disease surveillance priorities, and evolving access to modern diagnostics. China and India carry substantial UTI volumes and rising resistance concerns, making scalable diagnostics, urine culture access, and stewardship essential for both outpatient and inpatient settings. Japan, South Korea, and Australia have advanced healthcare infrastructure, strong diagnostic quality expectations, and growing interest in prevention strategies for aging populations, recurrent UTI patients, and catheter-associated infection reduction.

Actionable Recommendations for UTI Industry Leaders

Industry leaders should align product strategy with antimicrobial stewardship by prioritizing diagnostics and therapeutics that reduce unnecessary antibiotic exposure and support targeted treatment. Companies should invest in rapid susceptibility testing, molecular panels for complicated UTI, and digital clinical decision support that integrates with electronic health records, laboratory information systems, and local resistance data.

Manufacturers and service providers should segment the UTI market by care setting: telehealth and retail care for uncomplicated UTI, hospital systems for CAUTI prevention and complicated infection, and specialist care for recurrent UTI. Partnerships with laboratories, women’s health platforms, payers, public health stakeholders, and health systems can accelerate adoption when solutions demonstrate reduced time to appropriate therapy, fewer repeat visits, lower hospitalization risk, improved patient adherence, and measurable stewardship value.

Research Methodology

This executive summary is based on secondary research from peer-reviewed clinical literature, public health agencies, regulatory guidance, and recognized professional organizations, including CDC, WHO, NIH, IDSA, EAU, national antimicrobial resistance surveillance programs, and published infection-control evidence. The analysis prioritizes validated epidemiology, clinical practice trends, diagnostics adoption, antimicrobial resistance patterns, healthcare-associated infection prevention, and regional healthcare infrastructure indicators.

Insights were synthesized through cross-comparison of guideline updates, surveillance findings, hospital infection-prevention priorities, and technology adoption signals. Market interpretation focuses on evidence-backed drivers rather than unsupported projections, with emphasis on clinical utility, regulatory readiness, reimbursement feasibility, interoperability, stewardship alignment, and operational adoption across outpatient, inpatient, and long-term care environments.

Conclusion

The urinary tract infection market is entering a more precision-oriented phase as antimicrobial resistance, recurrent infection burden, and healthcare access pressures reshape demand. Growth will increasingly favor solutions that improve diagnostic certainty, shorten time to appropriate therapy, prevent catheter-associated infections, and reduce unnecessary antibiotic use.

Organizations that combine validated UTI diagnostics, AI-enabled workflows, stewardship-aligned therapeutics, and patient-centered care models will be best positioned to lead. The strongest opportunities will emerge where clinical evidence, affordability, interoperability, and regional implementation needs are addressed together.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Urinary Tract Infection Market, by Treatment
7.1. Introduction
7.2. Antibiotics
7.2.1. Fosfomycin
7.2.2. Nitrofurantoin
7.2.3. Trimethoprim/Sulfamethoxazole
7.2.4. Penicillins
7.2.5. Cephalosporins
7.2.6. Fluoroquinolones
7.3. Non Antibiotic Therapies
7.3.1. D-mannose
7.3.2. Probiotics
7.3.3. Immunomodulatory Supplements
8. Urinary Tract Infection Market, by Diagnosis Method
8.1. Introduction
8.2. Urinalysis
8.3. Urine Culture
8.4. Dipstick Tests
8.5. Molecular Diagnostics
8.6. Point-of-Care Testing
9. Urinary Tract Infection Market, by Infection Type
9.1. Introduction
9.2. Uncomplicated Cystitis
9.3. Complicated Urinary Tract Infection
9.4. Pyelonephritis
9.5. Recurrent Urinary Tract Infection
9.6. Catheter-Associated Urinary Tract Infection
9.7. Asymptomatic Bacteriuria
10. Urinary Tract Infection Market, by Age Group
10.1. Introduction
10.2. Adults
10.3. Geriatrics
10.4. Pediatrics
11. Urinary Tract Infection Market, by Infection Site
11.1. Introduction
11.2. Lower Tract Infection
11.2.1. Cystitis
11.2.2. Urethritis
11.3. Upper Tract Infection
11.3.1. Pyelonephritis
11.3.2. Ureteritis
12. Urinary Tract Infection Market, by Route Of Administration
12.1. Introduction
12.2. Oral Route
12.3. Intravenous Route
12.4. Intramuscular Route
12.5. Intravesical Route
13. Urinary Tract Infection Market, by Pathogen Type
13.1. Introduction
13.2. Bacterial Pathogens
13.2.1. Escherichia Coli
13.2.2. Klebsiella Species
13.2.3. Proteus Species
13.2.4. Pseudomonas Aeruginosa
13.2.5. Enterococcus Species
13.2.6. Staphylococcus Saprophyticus
13.3. Fungal Pathogens
13.4. Viral Pathogens
13.5. Parasitic Pathogens
14. Urinary Tract Infection Market, by End User
14.1. Introduction
14.2. Clinics & Outpatient Centers
14.3. Homecare Settings
14.4. Hospitals
14.5. Diagnostic Laboratories
14.6. Long-Term Care Facilities
15. Urinary Tract Infection Market, by Region
15.1. Asia-Pacific
15.2. Europe
15.3. North America
15.4. Latin America
15.5. Africa
15.6. Middle East
16. Urinary Tract Infection Market, by Group
16.1. NATO
16.2. G7
16.3. European Union
16.4. BRICS
16.5. ASEAN
16.6. GCC
17. Urinary Tract Infection Market, by Country
17.1. United States
17.2. China
17.3. Japan
17.4. Germany
17.5. India
17.6. United Kingdom
17.7. France
17.8. Canada
17.9. Australia
17.10. Italy
17.11. South Korea
17.12. Brazil
17.13. Mexico
17.14. Russia
17.15. Spain
18. Competitive Landscape
18.1. Market Share Analysis, 2025
18.2. FPNV Positioning Matrix, 2025
18.3. Market Concentration Analysis, 2025
18.3.1. Concentration Ratio (CR)
18.3.2. Herfindahl Hirschman Index (HHI)
18.4. Recent Developments & Impact Analysis, 2025
18.5. Product Portfolio Analysis, 2025
18.6. Benchmarking Analysis, 2025
19. Company Profiles
19.1. AbbVie Inc.
19.2. Almirall, SA
19.3. Aspen Pharmacare Holdings Limited
19.4. AstraZeneca PLC
19.5. Bayer AG
19.6. Beckman Coulter, Inc.
19.7. Boehringer Ingelheim International GmbH
19.8. Bristol-Myers Squibb Company
19.9. Cipla Limited
19.10. Dr Reddys Laboratories Ltd.
19.11. Eli Lilly and Company
19.12. F Hoffmann-La Roche AG
19.13. GlaxoSmithKline PLC
19.14. Johnson & Johnson Services, Inc.
19.15. Lupin Ltd.
19.16. Merck & Co Inc.
19.17. Novartis AG
19.18. Novo Nordisk A/S
19.19. Pfizer Inc.
19.20. PhenUtest Diagnostics Ltd.
19.21. Randox Laboratories Ltd.
19.22. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
19.23. Shionogi & Co, Ltd.
19.24. Siemens Healthineers AG
19.25. Sun Pharmaceutical Industries Limited
19.26. Sysmex Corporation
19.27. Teva Pharmaceutical Industries Ltd.
19.28. URIT Medical Electronic Co., Ltd.
19.29. Viatris Inc
List of Figures
FIGURE 1. GLOBAL URINARY TRACT INFECTION MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL URINARY TRACT INFECTION MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL URINARY TRACT INFECTION MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL URINARY TRACT INFECTION MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL URINARY TRACT INFECTION MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2025 VS 2032 (%)
FIGURE 7. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY DIAGNOSIS METHOD, 2025 VS 2032 (%)
FIGURE 9. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY DIAGNOSIS METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY INFECTION TYPE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY INFECTION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2025 VS 2032 (%)
FIGURE 13. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY INFECTION SITE, 2025 VS 2032 (%)
FIGURE 15. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY INFECTION SITE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY PATHOGEN TYPE, 2025 VS 2032 (%)
FIGURE 19. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY PATHOGEN TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 21. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 23. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 25. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 27. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. GLOBAL URINARY TRACT INFECTION MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 29. GLOBAL URINARY TRACT INFECTION MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL URINARY TRACT INFECTION MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL URINARY TRACT INFECTION MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL ANTIBIOTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL ANTIBIOTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL ANTIBIOTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL FOSFOMYCIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL FOSFOMYCIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL FOSFOMYCIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL NITROFURANTOIN MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL NITROFURANTOIN MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL NITROFURANTOIN MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL TRIMETHOPRIM/SULFAMETHOXAZOLE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL TRIMETHOPRIM/SULFAMETHOXAZOLE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL TRIMETHOPRIM/SULFAMETHOXAZOLE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL PENICILLINS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL PENICILLINS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL PENICILLINS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL CEPHALOSPORINS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL CEPHALOSPORINS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL CEPHALOSPORINS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL FLUOROQUINOLONES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL FLUOROQUINOLONES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL FLUOROQUINOLONES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL NON ANTIBIOTIC THERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL NON ANTIBIOTIC THERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL NON ANTIBIOTIC THERAPIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL D-MANNOSE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL D-MANNOSE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL D-MANNOSE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL PROBIOTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL PROBIOTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL PROBIOTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL IMMUNOMODULATORY SUPPLEMENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL IMMUNOMODULATORY SUPPLEMENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL IMMUNOMODULATORY SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY DIAGNOSIS METHOD, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL URINALYSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL URINALYSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL URINALYSIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL URINE CULTURE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL URINE CULTURE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL URINE CULTURE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL DIPSTICK TESTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL DIPSTICK TESTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL DIPSTICK TESTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL POINT-OF-CARE TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL POINT-OF-CARE TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL POINT-OF-CARE TESTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY INFECTION TYPE, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL UNCOMPLICATED CYSTITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL UNCOMPLICATED CYSTITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL UNCOMPLICATED CYSTITIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL COMPLICATED URINARY TRACT INFECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL COMPLICATED URINARY TRACT INFECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL COMPLICATED URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL PYELONEPHRITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL PYELONEPHRITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL PYELONEPHRITIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL RECURRENT URINARY TRACT INFECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL RECURRENT URINARY TRACT INFECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL RECURRENT URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL CATHETER-ASSOCIATED URINARY TRACT INFECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL CATHETER-ASSOCIATED URINARY TRACT INFECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL CATHETER-ASSOCIATED URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL ASYMPTOMATIC BACTERIURIA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL ASYMPTOMATIC BACTERIURIA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL ASYMPTOMATIC BACTERIURIA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL ADULTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL ADULTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL ADULTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL GERIATRICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL GERIATRICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL GERIATRICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL PEDIATRICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL PEDIATRICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL PEDIATRICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY INFECTION SITE, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL LOWER TRACT INFECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL LOWER TRACT INFECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL LOWER TRACT INFECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL CYSTITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL CYSTITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL CYSTITIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL URETHRITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL URETHRITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL URETHRITIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL UPPER TRACT INFECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL UPPER TRACT INFECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL UPPER TRACT INFECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL PYELONEPHRITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL PYELONEPHRITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL PYELONEPHRITIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL URETERITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL URETERITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL URETERITIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL ORAL ROUTE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL ORAL ROUTE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL ORAL ROUTE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL INTRAVENOUS ROUTE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL INTRAVENOUS ROUTE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL INTRAVENOUS ROUTE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL INTRAMUSCULAR ROUTE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL INTRAMUSCULAR ROUTE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL INTRAMUSCULAR ROUTE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL INTRAVESICAL ROUTE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL INTRAVESICAL ROUTE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL INTRAVESICAL ROUTE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL BACTERIAL PATHOGENS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL BACTERIAL PATHOGENS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL BACTERIAL PATHOGENS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 118. GLOBAL ESCHERICHIA COLI MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 119. GLOBAL ESCHERICHIA COLI MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 120. GLOBAL ESCHERICHIA COLI MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 121. GLOBAL KLEBSIELLA SPECIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 122. GLOBAL KLEBSIELLA SPECIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 123. GLOBAL KLEBSIELLA SPECIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 124. GLOBAL PROTEUS SPECIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 125. GLOBAL PROTEUS SPECIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 126. GLOBAL PROTEUS SPECIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 127. GLOBAL PSEUDOMONAS AERUGINOSA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 128. GLOBAL PSEUDOMONAS AERUGINOSA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 129. GLOBAL PSEUDOMONAS AERUGINOSA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 130. GLOBAL ENTEROCOCCUS SPECIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 131. GLOBAL ENTEROCOCCUS SPECIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 132. GLOBAL ENTEROCOCCUS SPECIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 133. GLOBAL STAPHYLOCOCCUS SAPROPHYTICUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 134. GLOBAL STAPHYLOCOCCUS SAPROPHYTICUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 135. GLOBAL STAPHYLOCOCCUS SAPROPHYTICUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 136. GLOBAL FUNGAL PATHOGENS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 137. GLOBAL FUNGAL PATHOGENS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 138. GLOBAL FUNGAL PATHOGENS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 139. GLOBAL VIRAL PATHOGENS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 140. GLOBAL VIRAL PATHOGENS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 141. GLOBAL VIRAL PATHOGENS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 142. GLOBAL PARASITIC PATHOGENS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 143. GLOBAL PARASITIC PATHOGENS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 144. GLOBAL PARASITIC PATHOGENS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 145. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 146. GLOBAL CLINICS & OUTPATIENT CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 147. GLOBAL CLINICS & OUTPATIENT CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 148. GLOBAL CLINICS & OUTPATIENT CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 149. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 150. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 151. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 152. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 153. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 154. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 155. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 156. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 157. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 158. GLOBAL LONG-TERM CARE FACILITIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 159. GLOBAL LONG-TERM CARE FACILITIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 160. GLOBAL LONG-TERM CARE FACILITIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 161. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 162. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 163. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2017-2032 (USD MILLION)
TABLE 164. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2017-2032 (USD MILLION)
TABLE 165. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2017-2032 (USD MILLION)
TABLE 166. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY DIAGNOSIS METHOD, 2017-2032 (USD MILLION)
TABLE 167. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY INFECTION TYPE, 2017-2032 (USD MILLION)
TABLE 168. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 169. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY INFECTION SITE, 2017-2032 (USD MILLION)
TABLE 170. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY LOWER TRACT INFECTION, 2017-2032 (USD MILLION)
TABLE 171. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY UPPER TRACT INFECTION, 2017-2032 (USD MILLION)
TABLE 172. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 173. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 174. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY BACTERIAL PATHOGENS, 2017-2032 (USD MILLION)
TABLE 175. ASIA-PACIFIC URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 176. EUROPE URINARY TRACT INFECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 177. EUROPE URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2017-2032 (USD MILLION)
TABLE 178. EUROPE URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2017-2032 (USD MILLION)
TABLE 179. EUROPE URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2017-2032 (USD MILLION)
TABLE 180. EUROPE URINARY TRACT INFECTION MARKET SIZE, BY DIAGNOSIS METHOD, 2017-2032 (USD MILLION)
TABLE 181. EUROPE URINARY TRACT INFECTION MARKET SIZE, BY INFECTION TYPE, 2017-2032 (USD MILLION)
TABLE 182. EUROPE URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 183. EUROPE URINARY TRACT INFECTION MARKET SIZE, BY INFECTION SITE, 2017-2032 (USD MILLION)
TABLE 184. EUROPE URINARY TRACT INFECTION MARKET SIZE, BY LOWER TRACT INFECTION, 2017-2032 (USD MILLION)
TABLE 185. EUROPE URINARY TRACT INFECTION MARKET SIZE, BY UPPER TRACT INFECTION, 2017-2032 (USD MILLION)
TABLE 186. EUROPE URINARY TRACT INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 187. EUROPE URINARY TRACT INFECTION MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 188. EUROPE URINARY TRACT INFECTION MARKET SIZE, BY BACTERIAL PATHOGENS, 2017-2032 (USD MILLION)
TABLE 189. EUROPE URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 190. NORTH AMERICA URINARY TRACT INFECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 191. NORTH AMERICA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2017-2032 (USD MILLION)
TABLE 192. NORTH AMERICA URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2017-2032 (USD MILLION)
TABLE 193. NORTH AMERICA URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2017-2032 (USD MILLION)
TABLE 194. NORTH AMERICA URINARY TRACT INFECTION MARKET SIZE, BY DIAGNOSIS METHOD, 2017-2032 (USD MILLION)
TABLE 195. NORTH AMERICA URINARY TRACT INFECTION MARKET SIZE, BY INFECTION TYPE, 2017-2032 (USD MILLION)
TABLE 196. NORTH AMERICA URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 197. NORTH AMERICA URINARY TRACT INFECTION MARKET SIZE, BY INFECTION SITE, 2017-2032 (USD MILLION)
TABLE 198. NORTH AMERICA URINARY TRACT INFECTION MARKET SIZE, BY LOWER TRACT INFECTION, 2017-2032 (USD MILLION)
TABLE 199. NORTH AMERICA URINARY TRACT INFECTION MARKET SIZE, BY UPPER TRACT INFECTION, 2017-2032 (USD MILLION)
TABLE 200. NORTH AMERICA URINARY TRACT INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 201. NORTH AMERICA URINARY TRACT INFECTION MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 202. NORTH AMERICA URINARY TRACT INFECTION MARKET SIZE, BY BACTERIAL PATHOGENS, 2017-2032 (USD MILLION)
TABLE 203. NORTH AMERICA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 204. LATIN AMERICA URINARY TRACT INFECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 205. LATIN AMERICA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2017-2032 (USD MILLION)
TABLE 206. LATIN AMERICA URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2017-2032 (USD MILLION)
TABLE 207. LATIN AMERICA URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2017-2032 (USD MILLION)
TABLE 208. LATIN AMERICA URINARY TRACT INFECTION MARKET SIZE, BY DIAGNOSIS METHOD, 2017-2032 (USD MILLION)
TABLE 209. LATIN AMERICA URINARY TRACT INFECTION MARKET SIZE, BY INFECTION TYPE, 2017-2032 (USD MILLION)
TABLE 210. LATIN AMERICA URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 211. LATIN AMERICA URINARY TRACT INFECTION MARKET SIZE, BY INFECTION SITE, 2017-2032 (USD MILLION)
TABLE 212. LATIN AMERICA URINARY TRACT INFECTION MARKET SIZE, BY LOWER TRACT INFECTION, 2017-2032 (USD MILLION)
TABLE 213. LATIN AMERICA URINARY TRACT INFECTION MARKET SIZE, BY UPPER TRACT INFECTION, 2017-2032 (USD MILLION)
TABLE 214. LATIN AMERICA URINARY TRACT INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 215. LATIN AMERICA URINARY TRACT INFECTION MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 216. LATIN AMERICA URINARY TRACT INFECTION MARKET SIZE, BY BACTERIAL PATHOGENS, 2017-2032 (USD MILLION)
TABLE 217. LATIN AMERICA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 218. AFRICA URINARY TRACT INFECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 219. AFRICA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2017-2032 (USD MILLION)
TABLE 220. AFRICA URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2017-2032 (USD MILLION)
TABLE 221. AFRICA URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2017-2032 (USD MILLION)
TABLE 222. AFRICA URINARY TRACT INFECTION MARKET SIZE, BY DIAGNOSIS METHOD, 2017-2032 (USD MILLION)
TABLE 223. AFRICA URINARY TRACT INFECTION MARKET SIZE, BY INFECTION TYPE, 2017-2032 (USD MILLION)
TABLE 224. AFRICA URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 225. AFRICA URINARY TRACT INFECTION MARKET SIZE, BY INFECTION SITE, 2017-2032 (USD MILLION)
TABLE 226. AFRICA URINARY TRACT INFECTION MARKET SIZE, BY LOWER TRACT INFECTION, 2017-2032 (USD MILLION)
TABLE 227. AFRICA URINARY TRACT INFECTION MARKET SIZE, BY UPPER TRACT INFECTION, 2017-2032 (USD MILLION)
TABLE 228. AFRICA URINARY TRACT INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 229. AFRICA URINARY TRACT INFECTION MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 230. AFRICA URINARY TRACT INFECTION MARKET SIZE, BY BACTERIAL PATHOGENS, 2017-2032 (USD MILLION)
TABLE 231. AFRICA URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 232. MIDDLE EAST URINARY TRACT INFECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 233. MIDDLE EAST URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2017-2032 (USD MILLION)
TABLE 234. MIDDLE EAST URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2017-2032 (USD MILLION)
TABLE 235. MIDDLE EAST URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2017-2032 (USD MILLION)
TABLE 236. MIDDLE EAST URINARY TRACT INFECTION MARKET SIZE, BY DIAGNOSIS METHOD, 2017-2032 (USD MILLION)
TABLE 237. MIDDLE EAST URINARY TRACT INFECTION MARKET SIZE, BY INFECTION TYPE, 2017-2032 (USD MILLION)
TABLE 238. MIDDLE EAST URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 239. MIDDLE EAST URINARY TRACT INFECTION MARKET SIZE, BY INFECTION SITE, 2017-2032 (USD MILLION)
TABLE 240. MIDDLE EAST URINARY TRACT INFECTION MARKET SIZE, BY LOWER TRACT INFECTION, 2017-2032 (USD MILLION)
TABLE 241. MIDDLE EAST URINARY TRACT INFECTION MARKET SIZE, BY UPPER TRACT INFECTION, 2017-2032 (USD MILLION)
TABLE 242. MIDDLE EAST URINARY TRACT INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 243. MIDDLE EAST URINARY TRACT INFECTION MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 244. MIDDLE EAST URINARY TRACT INFECTION MARKET SIZE, BY BACTERIAL PATHOGENS, 2017-2032 (USD MILLION)
TABLE 245. MIDDLE EAST URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 246. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 247. NATO URINARY TRACT INFECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 248. NATO URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2017-2032 (USD MILLION)
TABLE 249. NATO URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2017-2032 (USD MILLION)
TABLE 250. NATO URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2017-2032 (USD MILLION)
TABLE 251. NATO URINARY TRACT INFECTION MARKET SIZE, BY DIAGNOSIS METHOD, 2017-2032 (USD MILLION)
TABLE 252. NATO URINARY TRACT INFECTION MARKET SIZE, BY INFECTION TYPE, 2017-2032 (USD MILLION)
TABLE 253. NATO URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 254. NATO URINARY TRACT INFECTION MARKET SIZE, BY INFECTION SITE, 2017-2032 (USD MILLION)
TABLE 255. NATO URINARY TRACT INFECTION MARKET SIZE, BY LOWER TRACT INFECTION, 2017-2032 (USD MILLION)
TABLE 256. NATO URINARY TRACT INFECTION MARKET SIZE, BY UPPER TRACT INFECTION, 2017-2032 (USD MILLION)
TABLE 257. NATO URINARY TRACT INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 258. NATO URINARY TRACT INFECTION MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 259. NATO URINARY TRACT INFECTION MARKET SIZE, BY BACTERIAL PATHOGENS, 2017-2032 (USD MILLION)
TABLE 260. NATO URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 261. G7 URINARY TRACT INFECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 262. G7 URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2017-2032 (USD MILLION)
TABLE 263. G7 URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2017-2032 (USD MILLION)
TABLE 264. G7 URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2017-2032 (USD MILLION)
TABLE 265. G7 URINARY TRACT INFECTION MARKET SIZE, BY DIAGNOSIS METHOD, 2017-2032 (USD MILLION)
TABLE 266. G7 URINARY TRACT INFECTION MARKET SIZE, BY INFECTION TYPE, 2017-2032 (USD MILLION)
TABLE 267. G7 URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 268. G7 URINARY TRACT INFECTION MARKET SIZE, BY INFECTION SITE, 2017-2032 (USD MILLION)
TABLE 269. G7 URINARY TRACT INFECTION MARKET SIZE, BY LOWER TRACT INFECTION, 2017-2032 (USD MILLION)
TABLE 270. G7 URINARY TRACT INFECTION MARKET SIZE, BY UPPER TRACT INFECTION, 2017-2032 (USD MILLION)
TABLE 271. G7 URINARY TRACT INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 272. G7 URINARY TRACT INFECTION MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 273. G7 URINARY TRACT INFECTION MARKET SIZE, BY BACTERIAL PATHOGENS, 2017-2032 (USD MILLION)
TABLE 274. G7 URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 275. EUROPEAN UNION URINARY TRACT INFECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 276. EUROPEAN UNION URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2017-2032 (USD MILLION)
TABLE 277. EUROPEAN UNION URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2017-2032 (USD MILLION)
TABLE 278. EUROPEAN UNION URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2017-2032 (USD MILLION)
TABLE 279. EUROPEAN UNION URINARY TRACT INFECTION MARKET SIZE, BY DIAGNOSIS METHOD, 2017-2032 (USD MILLION)
TABLE 280. EUROPEAN UNION URINARY TRACT INFECTION MARKET SIZE, BY INFECTION TYPE, 2017-2032 (USD MILLION)
TABLE 281. EUROPEAN UNION URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 282. EUROPEAN UNION URINARY TRACT INFECTION MARKET SIZE, BY INFECTION SITE, 2017-2032 (USD MILLION)
TABLE 283. EUROPEAN UNION URINARY TRACT INFECTION MARKET SIZE, BY LOWER TRACT INFECTION, 2017-2032 (USD MILLION)
TABLE 284. EUROPEAN UNION URINARY TRACT INFECTION MARKET SIZE, BY UPPER TRACT INFECTION, 2017-2032 (USD MILLION)
TABLE 285. EUROPEAN UNION URINARY TRACT INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 286. EUROPEAN UNION URINARY TRACT INFECTION MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 287. EUROPEAN UNION URINARY TRACT INFECTION MARKET SIZE, BY BACTERIAL PATHOGENS, 2017-2032 (USD MILLION)
TABLE 288. EUROPEAN UNION URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 289. BRICS URINARY TRACT INFECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 290. BRICS URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2017-2032 (USD MILLION)
TABLE 291. BRICS URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2017-2032 (USD MILLION)
TABLE 292. BRICS URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2017-2032 (USD MILLION)
TABLE 293. BRICS URINARY TRACT INFECTION MARKET SIZE, BY DIAGNOSIS METHOD, 2017-2032 (USD MILLION)
TABLE 294. BRICS URINARY TRACT INFECTION MARKET SIZE, BY INFECTION TYPE, 2017-2032 (USD MILLION)
TABLE 295. BRICS URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 296. BRICS URINARY TRACT INFECTION MARKET SIZE, BY INFECTION SITE, 2017-2032 (USD MILLION)
TABLE 297. BRICS URINARY TRACT INFECTION MARKET SIZE, BY LOWER TRACT INFECTION, 2017-2032 (USD MILLION)
TABLE 298. BRICS URINARY TRACT INFECTION MARKET SIZE, BY UPPER TRACT INFECTION, 2017-2032 (USD MILLION)
TABLE 299. BRICS URINARY TRACT INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 300. BRICS URINARY TRACT INFECTION MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 301. BRICS URINARY TRACT INFECTION MARKET SIZE, BY BACTERIAL PATHOGENS, 2017-2032 (USD MILLION)
TABLE 302. BRICS URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 303. ASEAN URINARY TRACT INFECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 304. ASEAN URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2017-2032 (USD MILLION)
TABLE 305. ASEAN URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2017-2032 (USD MILLION)
TABLE 306. ASEAN URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2017-2032 (USD MILLION)
TABLE 307. ASEAN URINARY TRACT INFECTION MARKET SIZE, BY DIAGNOSIS METHOD, 2017-2032 (USD MILLION)
TABLE 308. ASEAN URINARY TRACT INFECTION MARKET SIZE, BY INFECTION TYPE, 2017-2032 (USD MILLION)
TABLE 309. ASEAN URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 310. ASEAN URINARY TRACT INFECTION MARKET SIZE, BY INFECTION SITE, 2017-2032 (USD MILLION)
TABLE 311. ASEAN URINARY TRACT INFECTION MARKET SIZE, BY LOWER TRACT INFECTION, 2017-2032 (USD MILLION)
TABLE 312. ASEAN URINARY TRACT INFECTION MARKET SIZE, BY UPPER TRACT INFECTION, 2017-2032 (USD MILLION)
TABLE 313. ASEAN URINARY TRACT INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 314. ASEAN URINARY TRACT INFECTION MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 315. ASEAN URINARY TRACT INFECTION MARKET SIZE, BY BACTERIAL PATHOGENS, 2017-2032 (USD MILLION)
TABLE 316. ASEAN URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 317. GCC URINARY TRACT INFECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 318. GCC URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2017-2032 (USD MILLION)
TABLE 319. GCC URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2017-2032 (USD MILLION)
TABLE 320. GCC URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2017-2032 (USD MILLION)
TABLE 321. GCC URINARY TRACT INFECTION MARKET SIZE, BY DIAGNOSIS METHOD, 2017-2032 (USD MILLION)
TABLE 322. GCC URINARY TRACT INFECTION MARKET SIZE, BY INFECTION TYPE, 2017-2032 (USD MILLION)
TABLE 323. GCC URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 324. GCC URINARY TRACT INFECTION MARKET SIZE, BY INFECTION SITE, 2017-2032 (USD MILLION)
TABLE 325. GCC URINARY TRACT INFECTION MARKET SIZE, BY LOWER TRACT INFECTION, 2017-2032 (USD MILLION)
TABLE 326. GCC URINARY TRACT INFECTION MARKET SIZE, BY UPPER TRACT INFECTION, 2017-2032 (USD MILLION)
TABLE 327. GCC URINARY TRACT INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 328. GCC URINARY TRACT INFECTION MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 329. GCC URINARY TRACT INFECTION MARKET SIZE, BY BACTERIAL PATHOGENS, 2017-2032 (USD MILLION)
TABLE 330. GCC URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 331. GLOBAL URINARY TRACT INFECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 332. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 333. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2017-2032 (USD MILLION)
TABLE 334. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2017-2032 (USD MILLION)
TABLE 335. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2017-2032 (USD MILLION)
TABLE 336. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY DIAGNOSIS METHOD, 2017-2032 (USD MILLION)
TABLE 337. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY INFECTION TYPE, 2017-2032 (USD MILLION)
TABLE 338. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 339. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY INFECTION SITE, 2017-2032 (USD MILLION)
TABLE 340. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY LOWER TRACT INFECTION, 2017-2032 (USD MILLION)
TABLE 341. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY UPPER TRACT INFECTION, 2017-2032 (USD MILLION)
TABLE 342. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 343. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY PATHOGEN TYPE, 2017-2032 (USD MILLION)
TABLE 344. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY BACTERIAL PATHOGENS, 2017-2032 (USD MILLION)
TABLE 345. UNITED STATES URINARY TRACT INFECTION MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 346. CHINA URINARY TRACT INFECTION MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 347. CHINA URINARY TRACT INFECTION MARKET SIZE, BY TREATMENT, 2017-2032 (USD MILLION)
TABLE 348. CHINA URINARY TRACT INFECTION MARKET SIZE, BY ANTIBIOTICS, 2017-2032 (USD MILLION)
TABLE 349. CHINA URINARY TRACT INFECTION MARKET SIZE, BY NON ANTIBIOTIC THERAPIES, 2017-2032 (USD MILLION)
TABLE 350. CHINA URINARY TRACT INFECTION MARKET SIZE, BY DIAGNOSIS METHOD, 2017-2032 (USD MILLION)
TABLE 351. CHINA URINARY TRACT INFECTION MARKET SIZE, BY INFECTION TYPE, 2017-2032 (USD MILLION)
TABLE

Companies Mentioned

  • AbbVie Inc.
  • Almirall, SA
  • Aspen Pharmacare Holdings Limited
  • AstraZeneca PLC
  • Bayer AG
  • Beckman Coulter, Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Dr Reddys Laboratories Ltd.
  • Eli Lilly and Company
  • F Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Lupin Ltd.
  • Merck & Co Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • PhenUtest Diagnostics Ltd.
  • Randox Laboratories Ltd.
  • Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • Shionogi & Co, Ltd.
  • Siemens Healthineers AG
  • Sun Pharmaceutical Industries Limited
  • Sysmex Corporation
  • Teva Pharmaceutical Industries Ltd.
  • URIT Medical Electronic Co., Ltd.
  • Viatris Inc

Table Information

Report AttributeDetails
No. of Pages189
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 10.96 Billion
Forecasted Market Value ( USD ) by 2032 $ 16.62 Billion
Compound Annual Growth Rate7.1%
Regions CoveredGlobal
No. of Companies Mentioned29

Related Topics

Related Reports

Urinary Tract Infection Testing Market - Global Forecast 2026-2032 - Product Image

Urinary Tract Infection Testing Market - Global Forecast 2026-2032

  • Report
  • 191 Pages
  • Global
From
Genitourinary Drugs Market - Global Forecast 2026-2032 - Product Image

Genitourinary Drugs Market - Global Forecast 2026-2032

  • Report
  • 198 Pages
  • Global
From
Urinary Tract Infection Treatment - Global Strategic Business Report - Product Image

Urinary Tract Infection Treatment - Global Strategic Business Report

  • Report
  • 302 Pages
  • Global
From
Urinary Tract Infection Testing Market - Global Strategic Business Report - Product Image

Urinary Tract Infection Testing Market - Global Strategic Business Report

  • Report
  • 300 Pages
  • Global
From
Uncomplicated Urinary Tract Infection Treatment Market Report 2026 - Product Image

Uncomplicated Urinary Tract Infection Treatment Market Report 2026

  • Report
  • 250 Pages
  • Global
From

About the Urinary Tract Infection Drug Market

The Urinary Tract Infection Drug market is a subset of the Urological Disorders Drugs market. It is composed of drugs used to treat urinary tract infections (UTIs), which are caused by bacteria entering the urinary tract. These drugs are typically antibiotics, such as sulfonamides, cephalosporins, and fluoroquinolones. They are used to kill the bacteria and reduce the symptoms of the infection. Other drugs, such as antifungals, may also be used to treat UTIs. The Urinary Tract Infection Drug market is highly competitive, with many companies offering a variety of drugs. Some of the major players in the market include Pfizer, Merck, GlaxoSmithKline, AstraZeneca, Sanofi, and Novartis. These companies are constantly developing new drugs to treat UTIs, as well as other urological disorders. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.